Fusion Immunotherapeutic
Autoimmune Disease
Clinical TrialBeing evaluated
Key Facts
About HCW Biologics
HCW Biologics is developing a novel class of fusion immunotherapies targeting the interconnected biology of chronic inflammation and aging. Founded by Dr. Hing C. Wong, whose prior discovery led to the FDA-approved immunotherapy Anktiva, the company leverages two proprietary protein engineering platforms to create multi-functional biologics. Its strategy encompasses advancing internal clinical candidates while also commercializing platform-derived reagents for next-generation cell therapy manufacturing, aiming to create value through both therapeutic development and strategic partnerships.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Not Specified (Autoimmune Focus) | Narwhal Bio | Pre-clinical |
| Undisclosed Precision Biologic | Rhapsogen | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| GIM-407 | Georgiamune | Preclinical |
| Autoimmunity Program | Accipiter Biosciences | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Appus | BioVectis | Pre-clinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |